XTL Biopharmaceuticals Ltd: XTLbio appoints Stockbroker and Financial Adviser

The Board of XTL Biopharmaceuticals Ltd ("XTLbio" or the "Company") is pleased to announce the appointment of Code Securities Limited as the Company's stockbroker and financial adviser. The appointment is effective immediately.

CONTACTS

XTLbio
Dr. Martin Becker President and CEO		+972-8-930-4440
Financial Dynamics
David Yates, Sarah MacLeod		+44 (0) 20 7831 3113
Code Securities Limited
Christopher Collins		+44 (0) 20 7024 2000

NOTES TO EDITORS
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. XTLbio's HepeX? product line - now in clinical trials - has the potential to introduce revolutionary therapies for viral hepatitis,including prevention of re-infection in transplanted livers, the Company's primary focus, and a longer-term cocktail approach in treating chronic illness. XTLbio believes its primary competitive advantage lies in its patented Trimera? technology, which enables the development of fully human monoclonal antibodies and models of human disease for pre-clinical drug validation. Established in1993, XTLbio became a public company in 2000 with shares traded on the London Stock Exchange under the symbol XTL.

Code Securities Limited ("Code") is a newly formed London-based investment banking firm providing a full range of advisory, fundraising and stockbroking services for companies and investors in the European life sciences and medtech sectors. Code is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.